NAD+ and diabetes research in the Philippine health context

TL;DR

• NAD+ helps cells handle energy-transfer reactions, but an essential biological role does not mean that pushing its level higher will improve diabetes.¹
• Philippine health planning documents place diabetes among the country’s major noncommunicable disease concerns, giving careful metabolic research clear local relevance.²
• A small trial in women with prediabetes found better muscle insulin sensitivity, yet several other short human trials did not improve insulin sensitivity.³
• Mouse studies explain why the idea attracted attention, but their models cannot establish prevention, treatment, or long-term outcomes for Filipino patients.⁴

For Filipino readers, NAD+ can arrive wrapped in the language of energy, longevity, or “metabolic support.” The diabetes connection deserves a calmer reading. Diabetes already carries a visible health burden in the Philippines.² NAD+ research asks interesting questions about how cells manage fuel, but a useful question is not yet a clinical answer.³

First, what is NAD+?

NAD+ is short for nicotinamide adenine dinucleotide, a coenzyme that cells use in redox reactions—the handoffs of electrons that help release usable energy from carbohydrates, fats, and proteins.¹ It also supports enzymes involved in genome maintenance, gene activity, and communication inside cells.¹ The plus sign names its oxidized form, while NADH is the reduced form in the same cycle.¹ Cells reuse both forms as the cycle runs.¹

The body can build NAD from niacin-related compounds, including nicotinamide riboside, often shortened to NR.⁵ Nicotinamide mononucleotide, or NMN, is another intermediate studied as a way to influence this pathway.⁴ That biochemical logic explains the research interest, but it does not show that more NAD+ produces a better diabetes outcome.³

NAD-plus is named here only as the neutral catalog reference below.

Why the question matters in the Philippines

The Philippine Department of Health’s National Objectives for Health 2023–2028 cites estimated adult diabetes prevalence of 7.8% among women and 7.9% among men.² The same document records 26,774 deaths due to diabetes mellitus from January through September 2022.² Those figures come from different cited datasets and should not be blended into a current full-year estimate.²

WHO describes diabetes as a chronic disease that develops when the pancreas does not make enough insulin or the body cannot use insulin well.⁶ Insulin helps control glucose in the blood, and high glucose can damage nerves and blood vessels over time.⁶ This makes glucose control a serious health issue, not a trend reserved for wellness culture.⁶

The local relevance is therefore the burden of diabetes and the need for accurate reading.² Clear terms matter here.⁶

Mouse research built the early hypothesis

One key study examined NAD+ biology in mice with diabetes features linked to diet or age.⁴ A high-fat diet disrupted a pathway used to make NAD+ in metabolic organs.⁴ When researchers gave NMN, NAD+ levels were restored and glucose intolerance improved in the diet model.⁴ The age-based tests also reported better glucose intolerance and lipid profiles.⁴

These results joined a plausible pathway to whole-animal measurements, which is more informative than a cell dish alone.⁴ Yet the animals had controlled diets, genetic backgrounds, environments, and experimental exposures that do not reproduce the varied lives of people with diabetes.⁴ “Improved glucose intolerance in mice” must remain a mouse finding.⁴

This was still a test in mice.⁴ For a reader, the model name is key.⁴ The study supplied a reason to test the hypothesis in people; it did not establish a human treatment result.⁴

One small human trial found a narrow signal

A later double-blind trial enrolled 25 women past menopause who had prediabetes and overweight or obesity.⁷ Thirteen received NMN and 12 received placebo for 10 weeks.⁷ Researchers used a metabolic clamp, a controlled test of how the body handles glucose while insulin is held at a planned level.⁷

Insulin-stimulated glucose disposal increased in the NMN group, and muscle samples showed increased insulin-signaling activity.⁸ The improvement was specific rather than sweeping.⁸ Body composition, liver insulin sensitivity, fasting glucose, insulin, and several other circulating measures did not improve.⁸

This is a positive human result, but its boundaries matter.⁷ The trial was short.⁷ It came from a small, short trial in a narrowly defined group and did not test diabetes prevention, complications, or long-term clinical outcomes.⁸ It cannot answer what would happen in men, younger adults, or people already diagnosed with diabetes.⁷ The signal was narrow.⁸

Other human trials produced important null results

NR has also been tested in people with metabolic risk.⁹ In a 12-week randomized trial, 40 men with obesity and insulin resistance received NR or placebo.⁹ NR did not improve insulin sensitivity, the body’s own glucose production, glucose disposal, energy expenditure, lipid oxidation, or body composition.⁹

A six-week crossover study in 13 adults with overweight or obesity found that NR increased markers of NAD+ synthesis in skeletal muscle.¹⁰ Even with that biochemical change, insulin sensitivity and mitochondrial function did not improve.¹⁰ A separate 28-day study of 30 middle-aged or older adults found higher circulating NAD and related metabolites with an NMN preparation, but insulin sensitivity did not change in either group.¹¹

These null findings are not empty space.³ They show that reaching a pathway marker and changing a body measure are different steps.¹⁰ The pathway moved; the health measure did not.¹⁰ The result did not reach the next step.¹⁰

The endpoint matters more than the headline

“Raises NAD+” describes a cell-level result, while “improves insulin sensitivity” describes a body result measured by a set method.¹⁰ Neither phrase automatically means that diabetes was prevented, treated, or reversed.³ A trial must measure the claimed outcome in the right group and follow people long enough to support it.³ These are not the same test.³ That gap is the point.³

The four human trials here also should not be forced into one scoreboard.³ They tested NMN or NR, lasted from 28 days to 12 weeks, and enrolled different groups.³ One focused on postmenopausal women with prediabetes, while others enrolled people with overweight, obesity, or insulin resistance.⁷ Their measurement plans also differed.³

The fair summary is mixed: one small trial found a muscle-specific signal, while several trials reported no improvement in insulin sensitivity.³ That is more precise than a sweeping verdict.³

Mitochondria connect a wider research map

NAD+ research often appears beside mitochondrial research because energy handling depends on reactions inside and around these cellular structures.¹ Another research lane examines MOTS-c, a 16-amino-acid peptide encoded within mitochondrial DNA.¹² Its original paper reported insulin-sensitivity-related findings in mice exposed to high-fat feeding or aging conditions.¹²

That work is related by theme, not by equivalence.¹² MOTS-c is a peptide signal, while NAD+ is a coenzyme involved in many metabolic reactions.¹ The reported intervention findings for MOTS-c were preclinical, so they cannot establish a human diabetes outcome.¹² Placing the topics together should help readers see different research questions, not merge them into one claim.¹² The two paths are not the same.¹² One cannot stand in for the other.¹²

MOTS-c is named here only as the neutral catalog reference below.

Bottom line

NAD+ matters to ordinary cell biology, and diabetes matters deeply in the Philippine health context.¹ That combination makes the research worth following without turning it into a promise.² Mouse studies established a plausible metabolic hypothesis, not a human result.⁴ A small trial in women with prediabetes found improved muscle insulin sensitivity, while other short trials found biochemical changes without better insulin sensitivity.³

The most useful reading habit is to separate pathway, marker, body endpoint, and clinical outcome.¹⁰ Each answers a different question.³ For now, NAD+ and diabetes remain a developing research story whose human findings are mixed, tied to each study group, and too limited to support a broad conclusion.³

This article is educational research context, not medical advice. Catalog links are neutral references and do not imply a treatment or human-use recommendation.

Frequently asked questions

Is NAD+ a medicine for diabetes?

NAD+ is a coenzyme used in normal cellular metabolism.¹ The studies reviewed here do not establish it as a diabetes medicine.³ Human trials tested specific precursors in specific populations, and several did not improve insulin sensitivity.³ A biological pathway should not be mistaken for a demonstrated clinical use.¹

What is the difference between NAD+, NMN, and NR?

NAD+ is the coenzyme involved in energy-transfer and other cellular reactions.¹ NMN is an intermediate in NAD+ biosynthesis, while NR is a niacin-related precursor the body can use along that pathway.⁵ Their connection in biochemistry does not make their study findings or possible effects interchangeable.³

Did the human study prove that NMN prevents diabetes?

No. The 10-week trial measured muscle insulin sensitivity in 25 postmenopausal women with prediabetes and overweight or obesity.⁷ It found a muscle-specific improvement, but it did not test whether participants later developed diabetes or experienced fewer complications.⁸ Longer, larger outcome studies would answer different questions.⁸

Why do the negative NR trials matter?

They test whether animal and biochemical ideas survive controlled human measurement.⁹ One 12-week trial found no improvement across several glucose and energy outcomes, while a smaller crossover trial changed muscle NAD+ markers without improving insulin sensitivity.¹⁰ Both results help define where the evidence currently stops.³

Can higher blood or muscle NAD+ prove better glucose control?

No. A marker can confirm that a pathway responded without showing that glucose regulation improved.¹⁰ In one crossover trial, muscle markers of NAD+ synthesis increased while insulin sensitivity did not.¹⁰ Clinical meaning depends on the endpoint measured, the comparator, the participants, and the follow-up.³

Why mention the Philippines if the trials were conducted elsewhere?

The Philippine context comes from the country’s documented diabetes burden, not from a claim that these interventions were locally studied.² The DOH planning document reports prevalence estimates and a substantial 2022 mortality count.² Those facts make careful research literacy locally relevant while leaving unverified Philippine regulatory or availability questions unanswered.

Sources

Footnotes

1. Niacin: Fact Sheet for Health Professionals. NIH Office of Dietary Supplements explanation of niacin metabolism and NAD biology. An essential cellular role does not show that increasing NAD beyond ordinary physiology improves a disease outcome. ↩ ↩² ↩³ ↩⁴ ↩⁵ ↩⁶ ↩⁷ ↩⁸ ↩⁹ ↩¹⁰ ↩¹¹

2. National Objectives for Health 2023–2028. Philippine national health-planning document summarizing cited prevalence estimates and Philippine Statistics Authority mortality data. The prevalence figures are estimates from the sources cited by DOH, while the death count covers only January through September 2022 and should not be treated as a current full-year total. ↩ ↩² ↩³ ↩⁴ ↩⁵ ↩⁶ ↩⁷ ↩⁸ ↩⁹

3. Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women; A randomized placebo-controlled clinical trial of nicotinamide riboside in obese men: safety, insulin-sensitivity, and lipid-mobilizing effects; Nicotinamide riboside supplementation alters body composition and skeletal muscle acetylcarnitine concentrations in healthy obese humans; Nicotinamide Adenine Dinucleotide Augmentation in Overweight or Obese Middle-Aged and Older Adults: A Physiologic Study. Cross-study synthesis of four randomized human trials with distinct populations and protocols. This comparison explains heterogeneity; it is not a formal meta-analysis and does not prove that every future intervention will be ineffective. ↩ ↩² ↩³ ↩⁴ ↩⁵ ↩⁶ ↩⁷ ↩⁸ ↩⁹ ↩¹⁰ ↩¹¹ ↩¹² ↩¹³ ↩¹⁴ ↩¹⁵ ↩¹⁶ ↩¹⁷ ↩¹⁸ ↩¹⁹ ↩²⁰ ↩²¹

4. Nicotinamide mononucleotide, a key NAD(+) intermediate, treats the pathophysiology of diet- and age-induced diabetes in mice. Laboratory study of diet-induced and age-associated diabetes phenotypes in mice. These are mouse findings under controlled experimental conditions and do not establish a diabetes outcome in people. ↩ ↩² ↩³ ↩⁴ ↩⁵ ↩⁶ ↩⁷ ↩⁸ ↩⁹ ↩¹⁰ ↩¹¹ ↩¹² ↩¹³

5. Niacin: Fact Sheet for Health Professionals. NIH Office of Dietary Supplements fact sheet describing niacin forms and conversion to NAD. A precursor's place in a biochemical pathway does not establish clinical effectiveness or interchangeability among precursor forms. ↩ ↩²

6. Diabetes. WHO diabetes fact sheet updated in November 2024. This broad description does not diagnose an individual or distinguish every diabetes subtype. ↩ ↩² ↩³ ↩⁴

7. Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women. Small double-blind randomized controlled trial using metabolic clamps and muscle measurements. The narrow population, small sample, and short follow-up limit generalization to men, younger people, people with diagnosed diabetes, or long-term outcomes. ↩ ↩² ↩³ ↩⁴ ↩⁵ ↩⁶ ↩⁷ ↩⁸

8. Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women. Prespecified and supporting outcomes from the randomized trial in postmenopausal women with prediabetes. A muscle-specific physiological change is not evidence that NMN prevents or treats diabetes or improves long-term clinical outcomes. ↩ ↩² ↩³ ↩⁴ ↩⁵ ↩⁶ ↩⁷

9. A randomized placebo-controlled clinical trial of nicotinamide riboside in obese men: safety, insulin-sensitivity, and lipid-mobilizing effects. Double-blind placebo-controlled trial using a hyperinsulinemic-euglycemic clamp and imaging measures. The study tested one precursor, protocol, duration, and male population and does not settle every NAD-related intervention or population. ↩ ↩² ↩³ ↩⁴

10. Nicotinamide riboside supplementation alters body composition and skeletal muscle acetylcarnitine concentrations in healthy obese humans. Small randomized double-blind placebo-controlled crossover study with metabolic clamps and muscle biopsies. The sample was very small and the intervention was short, while a biochemical target change did not produce the tested insulin-sensitivity outcome. ↩ ↩² ↩³ ↩⁴ ↩⁵ ↩⁶ ↩⁷ ↩⁸ ↩⁹ ↩¹⁰

11. Nicotinamide Adenine Dinucleotide Augmentation in Overweight or Obese Middle-Aged and Older Adults: A Physiologic Study. Short randomized physiologic study with a 2:1 allocation to an NMN preparation or placebo. The study was small and short, and its other reported changes require confirmation in larger, longer trials. ↩

12. The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance. Mechanistic cell and mouse study introducing MOTS-c and examining skeletal-muscle and metabolic outcomes. The reported intervention findings were preclinical and do not establish a human diabetes outcome or a claim about any catalog product. ↩ ↩² ↩³ ↩⁴ ↩⁵ ↩⁶ ↩⁷